|
Phyisician Led CIMAvax-EGF lung biomarkers |
11/03/2021 |
CIM |
|
Phase III study of the Cuban vaccine candidate VCN7-T in patients from 1 to 18 years of age at risk of pneumococcal disease in Havana |
04/10/2023 |
FINLAY |
|
Phase III clinical trial: Dermofural®. Mild infection in diabetic foot ulcer |
24/04/2023 |
CBQ |
|
Phase II clinical trial, controlled, randomized, double-blind to assess the immunogenicity of live attenuated vaccine candidate against cholera CV638 . |
06/11/2014 |
FINLAY |
|
Phase I/II trial with the mutein no alfa of IL-2 |
03/02/2017 |
CIM |
|
Paclitaxel/Radiotherapy/Cisplatino for cervical cancer |
17/02/2017 |
SSA |
|
Oncoxin®-Viusid®- Quality of life of patients with metastatic colorectal adenocarcinoma-adults-Phase II |
05/06/2018 |
CATALYSIS |
|
Oncoxin-Viusid/Stomach and gastric esophagus union cancer / Adults / Phase II |
10/05/2018 |
CATALYSIS |
|
Oncoxin-Viusid-Advanced or metastatic ovarian epithelial cancer-Adult women-Phase II |
17/04/2018 |
CATALYSIS |
|
Oncoxin-Viusid / Pancreatic adenocarcinoma / Adults / Phase II |
01/08/2018 |
CATALYSIS |
|
Obex® - Overweight and Obese - Adults - Phase III |
17/04/2018 |
CATALYSIS |
|
NUTRIRES2 |
31/03/2022 |
SSA |
|
Nimotuzumab in the treatment of patients with acute respiratory difficulty syndrome (ARDS) |
03/03/2023 |
CIM |
|
Nimotuzumab in Non-Small Cell Lung Cancer (NSCLC) of inoperable stage III epidermoid histology, concomitant with Chemo and Radiotherapy (CRT) |
28/12/2018 |
CIM |
|
Nimotuzumab in COVID-19 |
21/05/2021 |
CIM |
|
Nimotuzumab for the treatment of high grade of malignancy tumors |
2013-02-01 |
CIMAB |
|
Nimotuzumab cold kit for the immunodiagnosis of solid tumors |
05/10/2018 |
CIM |
|
NGcGM3/VSSP in patients with metastatic hormone-receptor positive and HER2 negative breast cancer |
28/11/2016 |
CIM |
|
NGcGM3/VSSP and nimotuzumab in patients with triple negative breast cancer |
12/10/2016 |
CIM |
|
NeuroEPO-Stroke. Phase I-II |
11/09/2014 |
CIMAB |
